Post by pointman229 on Aug 13, 2014 14:07:30 GMT -5
This being my first post, so am bit nervous. I looked into the details of Sanofi/Regeneron partnership agreement for antibody commercialization, and it seemed comparable to what we have at hand: 65%-55% profit sharing depending on sales milestone, and $1 billion invested for antibody r&d over 8 years. Thats little under $130million annual. Not looking too deep into details, but at the first glance MNKD doesn't have it so bad?
" Development costs for drug candidates co-developed by the parties will be shared, with sanofi-aventis funding development costs up front and Regeneron reimbursing half of the development costs for all collaboration drug candidates from Regeneron's share of future profits from commercialization of collaboration products to the extent future profits are sufficient for this purpose. In the United States, profits will be shared equally, while outside the United States, profits will be split on a pre-determined sliding scale with sanofi-aventis' share ranging from 65 percent to 55 percent.
For any products successfully developed as part of the collaboration, sanofi-aventis will take the lead in commercialization activities and will consolidate the sales. Regeneron will have the right to co-promote any and all collaboration products worldwide. In addition, Regeneron is entitled to receive up to a total of $250 million of sales milestone payments when collaboration products achieve certain aggregate annual ex-U.S. sales levels, starting at $1 billion."
This is a 2009 expansion on top of the original agreement formed in 2007 I think...
Still learning, and will appreciate feedback, scrutiny. Thank you in advance!!
" Development costs for drug candidates co-developed by the parties will be shared, with sanofi-aventis funding development costs up front and Regeneron reimbursing half of the development costs for all collaboration drug candidates from Regeneron's share of future profits from commercialization of collaboration products to the extent future profits are sufficient for this purpose. In the United States, profits will be shared equally, while outside the United States, profits will be split on a pre-determined sliding scale with sanofi-aventis' share ranging from 65 percent to 55 percent.
For any products successfully developed as part of the collaboration, sanofi-aventis will take the lead in commercialization activities and will consolidate the sales. Regeneron will have the right to co-promote any and all collaboration products worldwide. In addition, Regeneron is entitled to receive up to a total of $250 million of sales milestone payments when collaboration products achieve certain aggregate annual ex-U.S. sales levels, starting at $1 billion."
This is a 2009 expansion on top of the original agreement formed in 2007 I think...
Still learning, and will appreciate feedback, scrutiny. Thank you in advance!!
